← FDA DRUG APPROVALS

FDA ANDA · ANDA084294

CAFERGOT

Sponsor: CHARTWELL RX

APPLICATION
ANDA084294
TYPE
ANDA
ORIGINAL APPROVAL
1976-09-29
LATEST ACTION
2008-04-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CAFERGOT · ReferenceDiscontinued
CAFFEINE 100MG, ERGOTAMINE TARTRATE 1MG · TABLET · ORAL

Approval history

2008-04-14Labeling · Supplement 83AP
2003-10-03Labeling · Supplement 75AP
1999-07-26Manufacturing (CMC) · Supplement 72AP
1994-01-24Manufacturing (CMC) · Supplement 71AP
1987-02-03Manufacturing (CMC) · Supplement 70AP
1987-02-03Manufacturing (CMC) · Supplement 69AP
1986-02-05Manufacturing (CMC) · Supplement 68AP
1984-12-17Manufacturing (CMC) · Supplement 67AP
1984-10-03Manufacturing (CMC) · Supplement 64AP
1984-10-03Manufacturing (CMC) · Supplement 65AP
1984-07-26Manufacturing (CMC) · Supplement 66AP
1983-09-09Manufacturing (CMC) · Supplement 63AP
1983-07-18Manufacturing (CMC) · Supplement 61AP
1983-06-06Manufacturing (CMC) · Supplement 60AP
1983-03-24Manufacturing (CMC) · Supplement 58AP
1982-07-01Manufacturing (CMC) · Supplement 51AP
1982-07-01Manufacturing (CMC) · Supplement 52AP
1982-07-01Manufacturing (CMC) · Supplement 53AP
1976-09-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →